<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25924">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769273</url>
  </required_header>
  <id_info>
    <org_study_id>D029260</org_study_id>
    <nct_id>NCT02769273</nct_id>
  </id_info>
  <brief_title>Stellarex Vascular E-Registry</brief_title>
  <acronym>SAVER</acronym>
  <official_title>Stellarex Vascular E-Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectranetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectranetics Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, international, multi-center, single arm, observational study to continue to
      assess the treatment by the Stellarex™ OTW Drug-coated Angioplasty Balloon in superficial
      femoral and/or popliteal arteries according to the Instructions for Use in a broad,
      real-world, claudicant or ischemic rest pain patients population per the institution's
      standard practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint</measure>
    <time_frame>12 months post-procedure</time_frame>
    <description>Freedom from Clinically Driven Target Lesion Revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>12 months post-procedure</time_frame>
    <description>Freedom from device and procedure-related death through 30 days post-procedure and freedom from target limb major amputation and Clinically Driven Target Lesion Revascularization through 12 months post-procedure</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Transluminal Angioplasty</intervention_name>
    <other_name>Stellarex™ OTW Drug-coated Angioplasty Balloon</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic stenosis of the superficial femoral artery and/or popliteal
        artery intended to be treated with a Percutaneous Transluminal Angioplasty using the
        Stellarex OTW Drug -Coated Balloon
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients intended to be treated with Stellarex for de-novo or restenotic lesions of
             the femoro-popliteal arteries

          -  Rutherford Clinical Category (RCC) 2-3 or 4 indicated for a Percutaneous Transluminal
             Angioplasty according to local applicable guidelines

          -  Age ≥18 years old

          -  Life expectancy &gt; 1 year

          -  Is able and willing to provide written informed consent prior to enrollment in the
             study (as applicable)

          -  Is able and willing to come on site or to be contacted by phone for the follow-up

        Exclusion Criteria:

          -  Patients with any medical condition that would make him/her inappropriate for
             treatment with Stellarex as per Instructions for Use (IFU) or investigator's opinion

          -  Patient already enrolled in other investigational (interventional) studies that would
             interfere with study endpoints

          -  Patients that in the judgment of the investigator would need treatment below the knee
             before and/or during the index procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laure COUTROT</last_name>
    <phone>0033 1 40 98 08 77</phone>
    <email>laure.coutrot@bv.spnc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Wurstenberghs</last_name>
    </contact>
    <investigator>
      <last_name>Karen Wurstenberghs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imelda</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juergen Verbist</last_name>
    </contact>
    <investigator>
      <last_name>Juergen Verbist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint Blasius</name>
      <address>
        <city>Dendermond</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Deloose</last_name>
    </contact>
    <investigator>
      <last_name>Koen Deloose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Vermassen</last_name>
    </contact>
    <investigator>
      <last_name>Frank Vermassen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 23, 2016</lastchanged_date>
  <firstreceived_date>May 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
